Back to search

Switzerland· 66256002

Mebucaïne N, Lutschtabletten

A cetylpyridinium product containing cetylpyridinii chloridum, lidocaini hydrochloridum monohydricum, registered in Switzerland by Spirig HealthCare AG and dispensed under Swissmedic category D. The same ATC class is registered in 4 of our 19 countries.

Cat D (Swissmedic)ATC R02AA06

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedMebucaïne N, LutschtablettenATCR02AA06REGISTER NO.66256002PACKS LISTED0CHECKEDSeptember 12, 2026

Where it is registered

Cetylpyridinium is registered in 4 of 19 countries.

Countries holding a registration under ATC R02AA06 (cetylpyridinium), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 3 of them publish a price we can compare per daily dose

Cetylpyridinium · ATC R02AA06

4 / 19 countries

  • Canada
  • Czechiaprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
cetylpyridinii chloridum, lidocaini hydrochloridum monohydricum
Manufacturer
Spirig HealthCare AG
Country
Switzerland (CH)
ATC code
R02AA06
ATC class
Cetylpyridinium
Swissmedic category
D
Reimbursed
No
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for cetylpyridinium.

Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cetylpyridinium · interactions on record

1 record

  • 1 moderate

Most severe, free to view

  • Hyaluronic acidM09AX01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cetylpyridinium in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cetylpyridinium products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Bulgaria · Калгел
  • Czechia · Calgel
  • Estonia · Calgel
  • United Kingdom (Northern Ireland) · Bonjela Junior, Calgel Teething
  • Greece · Xylojell Plus
  • Hungary · Mebucain Mint
  • Latvia · Calgel
  • Poland · Calgel, Orofar Max
  • Romania · Calgel
  • Slovenia · Calgel
  • Slovakia · Calgel, Oroforte Menthol

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f4591829-404b-4660-9a9b-5114e2b27c8d
GET /v1/drugs/f4591829-404b-4660-9a9b-5114e2b27c8d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{}

See everything about cetylpyridinium.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.